31
2025
Lonza
CEO
Wolfgang
Wienand
CFO
Philippe
Deecke
Head IR
Daniel
Buchta
ZKB Analyst: Daniel Jelovcan
Group meeting, One-on-one
The new Lonza (without the former specialty chemicals business LSI) offers products and services exclusively for the pharmaceutical and healthcare industries and is one of the most important contract developers and manufacturers of chemically and, above all, biotechnologically manufactured active ingredients. With the Capsugel acquisition, Lonza became a leading capsule manufacturer and major formulation specialist. It also produces ingredients for dietary supplements. Important competitors are Boehringer Ingelheim, Samsung Biologics, Catalent, ThermoFisher, Wuxi Biologics, the German Merck, Fujifilm Diosynth and Siegfried.